FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.

ABSTRACT:

Background

Pancreatic Cancer is one of the most lethal cancers, with less than 8% of patients surviving 5 years following diagnosis. The last 40 years have seen only small incremental improvements in treatment options, highlighting the continued need to better define the cellular and molecular pathways contributing to therapy response and patient prognosis.

Methods

We combined CRISPR, shRNA and flow cytometry with mechanistic experiments using a Kras^G12Dp53^R172H mouse model of pancreatic cancer and analysis of publicly available human PDAC transcriptomic datasets.

Results

Here, we identify that expression of the immune checkpoint, Programmed Death Ligand 2 (PD-L2), is associated with poor prognosis, tumour grade, clinical stage and molecular subt

SUBMITTER: Davidson C 

PROVIDER: S-EPMC9643373 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature